Gerresheimer presents its new Clinical Trial Kit to accelerate drug development

- Gerresheimer AG — Gerresheimer presents its new Clinical Trial Kit at Pharmapack in Paris.

Düsseldorf/Paris, February 1, 2023. Gerresheimer presents its new Clinical Trial Kit at Pharmapack in Paris. This kit consists of sterile Gx RTF vials in nest and tub or tray with matching closures and is tailored to requirements to support the development of new drugs, vaccines and biologics in early phases. The Clinical Trial Kit is suitable for small batch manufacturing from first line trials to validation and clinical batches. It can be ordered in six different configurations of Gx RTF Glass Vials. Kits including Gx Elite and Gx RTF COP vials will follow soon.

“There are currently more than 3,000 injectable drug programs in pre-clinical and clinical phases. With our clinical trial kits and supportive services, we want to proactively support our customers by providing them with first-class primary packaging solutions,” said Jean-Edouard Rabier, Sales Development Manager and Director Project Management/Pharmaceutical Services and member of the Gx Biological Solutions Team.

Simplifying the clinical development of drugs
The Gerresheimer Clinical Trial Kit simplifies the clinical development of drugs by offering pre-tested and validated solutions that are readily usable for small batch sizes to replace commercial production. The major advantage of this concept is that companies can benefit from the exact same performance of the containers during commercialization as during research and development. This helps to shorten time to market and bring life-saving drugs to patients faster.

Sterile Gx RTF Vials and a selected range of stoppers and closure options
The kit provides a complete set of primary packaging container and containment solutions, especially selected for high value drugs and/or most complex and demanding drugs. The Clinical Trial Kit complies with GMP requirements for the production of clinical batches. It is currently offered in six different configurations with nest and tub or tray for filling volumes 2R RTF, 6R RTF and 10R RTF. Customers may receive a tailored kit made from a range of stopper and closure options selected using expertise advice. Each kit offers tried-and-tested product features, such as the integrity of the container system.

Additional integrated services
Gerresheimer accompanies and supports its customers' drug development from basic analysis to fill & finish service, i.e., from the early phase through to life-cycle management. For this purpose, Gerresheimer has developed a network of partners to support customers during the entire drug development journey. This includes expertise regarding regulatory implementation, development path and market approach, strategies for packaging and administration of drugs, as well as laboratory services. Analytical laboratory services include E&L studies (components and systems), material characterization according to ISO 10993-18:2020, biocompatibility studies according to the 10993 series, toxicological risk assessment and consulting services and BEP/BER writing services.

Formulation, fill & finish
Together with selected partners, Gerresheimer supports its customers throughout their journey from the early pre-clinical phase to the start of clinical and commercial batch supplies. Regardless of whether they are CROs, CMOs or CDMOs, Gerresheimer knows the right partners for a wide range of drugs including vaccines, mAbs, mRNA-based drugs and ATMPs.

Find out more: Clinical Trial Kit

Contact Press
Ueli Utzinger
Global Senior Director Marketing & Communication
T +49 211 6181-3 45
ueli.utzinger-remove@remove-gerresheimer.com

Contact trade press
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 211 6181-246
marion.stolzenwald-remove@remove-gerresheimer.com

About Gerresheimer

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 11,000 employees and generated annual revenues in 2021 of around EUR 1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.
www.gerresheimer.com

Back to overview